TICKERNERD
Menu
NERVNERVHealthcare · Biotechnology

NERV Stock Forecast: Minerva Neurosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$4.58
+16.84% on the day

The 3 Wall Street analysts covering Minerva Neurosciences, Inc. hold a median 12-month price target of $7.5 — +63.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$218.7M
Ticker Nerd rank
31 / 100
Median analyst target
$7.50
Analysts covering
3
Total return, dividends reinvested
1W
+7.3%
1M
+13.9%
YTD
+13.9%
1Y
+155.2%
From 52W high
−43.2%
From 52W low
+155.2%
$1.80
$8.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NERV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Minerva Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
72
Momentum
71
Size
68
Revisions
64
Value
35
Volatility
28
Quality
26
Growth
10
Issuance
5

Accruals (72): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NERV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NERV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26NERVHigh $14.00Median $7.50Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
1 Buy2 Hold0 Sell
Low $7.00Median $7.50High $14.00

The green dot is the last close — the median target sits +63.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
14 Aug 2026JefferiesUpgradeBuy$7.50 → $10
15 Apr 2026CitizensInitiatesMarket Outperform$14
12 Mar 2026HC Wainwright & Co.MaintainsNeutral—
6 Nov 2025HC Wainwright & Co.MaintainsNeutral—
26 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
6 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
7 Aug 2024HC Wainwright & Co.MaintainsNeutral—
2 May 2024HC Wainwright & Co.MaintainsNeutral—
27 Feb 2024HC Wainwright & Co.ReiteratesNeutral—
2 Aug 2023HC Wainwright & Co.MaintainsNeutral—
16 May 2023HC Wainwright & Co.ReiteratesNeutral—
2 May 2023HC Wainwright & Co.ReiteratesNeutral—
9 Mar 2023HC Wainwright & Co.ReiteratesNeutral—
10 Nov 2022HC Wainwright & Co.DowngradeNeutral—
17 Oct 2022JMP SecuritiesDowngradeMarket Perform—
4 Mar 2022HC Wainwright & Co.MaintainsBuy$10 → $5.00
8 June 2020HC Wainwright & Co.MaintainsBuy$20 → $10
19 Dec 2019H.C. WainwrightReiteratesBuy—
19 Dec 2019HC Wainwright & Co.ReiteratesBuy$22 → $20
19 Dec 2019JMP SecuritiesMaintainsMarket Outperform$20 → $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NERV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NERV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Minerva Neurosciences, Inc. (NERV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
−1.0×

Cheaper than 94% of US stocks

EV / EBITDA
−6.1×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
208.5%

Higher than 98% of US stocks

Return on assets
−35.0%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NERV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NERVMinerva Neurosciences, Inc.$218.7M
31
ALECAlector, Inc.$213.9M
41
IVVDInvivyd, Inc.$212.4M
19
ANTXAN2 Therapeutics, Inc.$215.3M
74
YDESYD Bio Ltd.$210.2M
53
TNXPTonix Pharmaceuticals Holding Corp.$218.0M
21
IMUXImmunic, Inc.$218.8M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Minerva Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NERV news & analysis

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

GlobeNewsWire · 7 Aug 2026neutral

Minerva Neurosciences reported financial results and business updates for the second quarter ended June 30, 2026. The confirmatory Phase 3 trial of roluperidone (MIN-101C19) is ongoing with topline efficacy data expected in the second half of 2027, and a Scientific Advisory Board of leading psychiatry and neuroscience experts has been established to guide the trial.

Why it matters — NERV watchers would care because progress updates on the confirmatory roluperidone Phase 3 trial, currently the only late-stage drug candidate for that high-need population, are central to the company's outlook.

FAQ

Frequently asked questions about NERV stock

What is the NERV stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Minerva Neurosciences, Inc. have a median 12-month price target of $7.5, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NERV stock a buy right now?

Of the 3 analysts covering Minerva Neurosciences, Inc., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Minerva Neurosciences, Inc. 31 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NERV?

As at 15 Aug 2026, Minerva Neurosciences, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (72 of 100).

Will NERV stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +63.8% from the last close, and Ticker Nerd's factor model ranks Minerva Neurosciences, Inc. 31 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NERV stock forecast for 2030?

No analyst covering Minerva Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NERV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.

How has NERV stock performed over the past year?

Minerva Neurosciences, Inc. returned +155.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Minerva Neurosciences, Inc. do?

Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates for central nervous system diseases.

What is the latest news on NERV?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates". Minerva Neurosciences reported financial results and business updates for the second quarter ended June 30, 2026. The confirmatory Phase 3 trial of roluperidone (MIN-101C19) is ongoing with topline efficacy data expected in the second half of 2027, and a Scientific Advisory Board of leading psychiatry and neuroscience experts has been established to guide the trial.

Company

About Minerva Neurosciences, Inc.

Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates for central nervous system diseases. Its lead product candidate, roluperidone, targets negative symptoms in patients with schizophrenia, such as blunted affect, alogia, avolition, anhedonia, and asociality, addressing a significant unmet medical need where no specific treatments are approved. The company also holds exclusive rights to MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, for Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences Inc. emphasizes innovative clinical trial designs with endpoints linked to patient benefits, recruiting suitable participants for its therapies. Operating in the biotechnology sector within healthcare, it concentrates on research, clinical development, and regulatory interactions for chronic, disabling neurologic and psychiatric conditions. Founded in 2007 and headquartered in Burlington, Massachusetts, the company advances its pipeline to enhance therapeutic options in CNS disorders.

CEO Dr. Remy Luthringer Ph.D. · 7 employees · United States · https://www.minervaneurosciences.com